Skip to main content
Outcomes in High-Risk Subgroups After Fixed-Duration Ibrutinib (Ibr) plus Venetoclax (Ven) for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Up to 5.5 Years of Follow-Up in the Phase 2 CAPTIVATE Study
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.